Latest Conference Articles

June 7th 2022, 12:45am

OncLive News Network: On Location at ASCO 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

June 7th 2022, 12:25am

ASCO Annual Meeting

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

June 7th 2022, 12:15am

ASCO Annual Meeting

Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.

June 7th 2022, 12:13am

Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.

June 7th 2022, 12:04am

ASCO Annual Meeting

FOLFOXIRI plus bevacizumab led to a significant improvement in progression-free survival, objective response rate, and R0/1 resections vs FOLFOX/FOLFIRI plus bevacizumab but resulted in increased toxicity in patients with initially unresectable colorectal cancer liver metastases and right-sided and/or RAS- or BRAF V600E–mutated primary tumors.

June 7th 2022, 12:00am

ASCO Annual Meeting

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

June 6th 2022, 11:45pm

ASCO Annual Meeting

The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

June 6th 2022, 11:35pm

ASCO Annual Meeting

Ribociclib plus an aromatase inhibitor elicited improved symptom-related quality of life outcomes compared with abemaciclib plus an aromatase inhibitor as first-line therapy in postmenopausal patients with hormone receptor–positive, HER2–negative advanced breast cancer, according to findings from a matching-adjusted indirect comparison study.

June 6th 2022, 11:15pm

ASCO Annual Meeting

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

June 6th 2022, 10:48pm

Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.

June 6th 2022, 10:46pm

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

June 6th 2022, 10:45pm

ASCO Annual Meeting

Bevacizumab combined with first-line chemotherapy was shown to improve progression-free survival and overall survival in patients with advanced ovarian clear cell carcinoma.

June 6th 2022, 10:30pm

ASCO Annual Meeting

Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.

June 6th 2022, 10:17pm

Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.

June 6th 2022, 10:15pm

ASCO Annual Meeting

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

June 6th 2022, 10:12pm

ASCO Annual Meeting

Twice-daily oral ruxolitinib plus carboplatin and paclitaxel given as frontline neoadjuvant and post-surgical treatment to patients with stage III or IV ovarian cancer was found to be feasible and to improve progression-free survival compared with chemotherapy alone.

June 6th 2022, 10:11pm

Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.

June 6th 2022, 10:06pm

Resection of the primary tumor prior to systemic therapy was not found to extend overall survival in patients with asymptomatic colon and high rectal cancer who had synchronous unresectable metastases.

June 6th 2022, 9:20pm

ASCO Annual Meeting

Higher treatment discontinuation rates with abemaciclib were associated with factors including age of 65 year or older, enrollment in either North America or Europe, an ECOG performance status of 1, postmenopausal status, 1 to 3 positive lymph nodes, and 4 or more preexisting comorbidities in patients with hormone receptor–positive, HER2-negative high-risk early breast cancer.

June 6th 2022, 8:55pm

ASCO Annual Meeting

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.